Back to top
more

BioCryst Pharmaceuticals (BCRX)

(Real Time Quote from BATS)

$8.10 USD

8.10
482,149

+0.32 (4.11%)

Updated Nov 11, 2024 12:46 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (69 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Top Ranked Momentum Stocks to Buy for March 9th

by Zacks Equity Research

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, March 9th

BioCryst Pharmaceuticals (BCRX) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

BioCryst (BCRX) delivered earnings and revenue surprises of 92.00% and 230.49%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

BioCryst Pharmaceuticals (BCRX) in Focus: Stock Moves 8.5% Higher

by Zacks Equity Research

BioCryst Pharmaceuticals (BCRX) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

Will BioCryst Pharmaceuticals (BCRX) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

BioCryst (BCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Is the Options Market Predicting a Spike in BioCryst (BCRX) Stock?

by Zacks Equity Research

Investors need to pay close attention to BioCryst (BCRX) stock based on the movements in the options market lately.

BioCryst Submits NDA for Hereditary Angioedema Candidate

by Zacks Equity Research

BioCryst (BCRX) files a new drug application to the FDA for once-daily berotralstat (BCX7353), which is being developed for the prevention of hereditary angioedema attacks.

Implied Volatility Surging for BioCryst (BCRX) Stock Options

by Zacks Equity Research

Investors need to pay close attention to BioCryst (BCRX) stock based on the movements in the options market lately.

BioCryst Pharmaceuticals (BCRX) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

BioCryst (BCRX) delivered earnings and revenue surprises of -9.68% and -60.92%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate BioCryst Pharmaceuticals (BCRX) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

BioCryst (BCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate BioCryst Pharmaceuticals (BCRX) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

BioCryst (BCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BioCryst Pharmaceuticals (BCRX) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

BioCryst (BCRX) delivered earnings and revenue surprises of -9.68% and -42.43%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: BioCryst Pharmaceuticals (BCRX) Q2 Earnings Expected to Decline

by Zacks Equity Research

BioCryst (BCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BioCryst Down Despite Hereditary Angioedema Study Meets Goal

by Zacks Equity Research

BioCryst's (BCRX) phase III study on BCX7353 for the prevention of hereditary angioedema attacks meets the primary endpoint for both doses (110mg/150 mg). Shares depreciate despite this upside.

Do Options Traders Know Something About BioCryst Pharmaceuticals (BCRX) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to BioCryst Pharmaceuticals (BCRX) stock based on the movements in the options market lately.

BioCryst Pharmaceuticals (BCRX) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

BioCryst (BCRX) delivered earnings and revenue surprises of 0.00% and 101.96%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate BioCryst Pharmaceuticals (BCRX) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

BioCryst (BCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Implied Volatility Surging for BioCryst Pharmaceuticals (BCRX) Stock Options

by Zacks Equity Research

BioCryst Pharmaceuticals (BCRX) needs investors to pay close attention to the stock based on moves in the options market lately.

Analysts Estimate BioCryst Pharmaceuticals (BCRX) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

BioCryst (BCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BioCryst Pharmaceuticals (BCRX) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

BioCryst (BCRX) delivered earnings and revenue surprises of -12.00% and -42.60%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: BioCryst Pharmaceuticals (BCRX) Q3 Earnings Expected to Decline

by Zacks Equity Research

BioCryst (BCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Grifols (GRFS) Surges: Stock Moves 5.4% Higher

by Zacks Equity Research

Grifols (GRFS) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

BioCryst Pharmaceuticals (BCRX) Looks Good: Stock Adds 6% in Session

by Zacks Equity Research

BioCryst Pharmaceuticals (BCRX) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

    BioCryst Pharmaceuticals (BCRX) Reports Q2 Loss, Tops Revenue Estimates

    by Zacks Equity Research

    BioCryst (BCRX) delivered earnings and revenue surprises of 17.39% and 228.79%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

      Idera Stock Down, Study on Dermatomyositis Candidate Fails

      by Zacks Equity Research

      Shares of Idera (IDRA) decline following the failure of a phase II study of its pipeline candidate, IMO-8400, on adult patients with dermatomyositis.

        Options Traders Expect Huge Moves in BioCryst (BCRX) Stock

        by Zacks Equity Research

        Investors in BioCryst (BCRX) need to pay close attention to the stock based on moves in the options market lately.